Nasofan (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors in nasal mucosal cells, modulating gene expression to suppress the release of inflammatory cytokines and chemokines. This reduces inflammatory cell infiltration, edema, and mucus production, leading to symptom relief.

The prescribed dose of Nasofan is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Dosage instructions are provided on the product label and should be followed exactly as directed by a healthcare professional.

Safety data for fluticasone propionate in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the prescribing physician.

To place an order, submit an enquiry on the Nasofan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasofan’s active ingredient, fluticasone propionate, is a high‑potency glucocorticoid with low systemic bioavailability, similar to other prescription nasal steroids such as mometasone furoate. Clinical efficacy and safety profiles are comparable, but individual response and tolerability may vary.

Store Nasofan at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

Nasofan is delivered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if required.

Serious risks, though rare, include nasal septal perforation, adrenal suppression with prolonged high‑dose use, cataract formation, glaucoma, and severe allergic reactions such as anaphylaxis. Patients should be monitored for these events, especially during long‑term therapy.

Nasofan should be avoided in individuals with known hypersensitivity to fluticasone propionate or any component of the formulation, and in patients with active untreated nasal infections. Caution is also advised for those with uncontrolled glaucoma, cataracts, or systemic conditions that could be worsened by corticosteroids.